Classification of current anticancer immunotherapies
Lorenzo Galluzzi(Fox Chase Cancer Center), Enrico Lugli(Humanitas University), Guido Kroemer(Institut Universitaire de France), Klas Kärre(Karolinska Institutet), Dirk Jäger(German Cancer Research Center), John M. Kirkwood(UPMC Hillman Cancer Center), Jean-Pierre Abastado(Agency for Science, Technology and Research), Giuseppe Giaccone(Cornell University), Michael T. Lotze(University of Pittsburgh), Laura Bracci(Istituto Superiore di Sanità), Lisa M. Coussens(Oregon Health & Science University), Roland Liblau(Centre National de la Recherche Scientifique), Rolf Kiessling(Unknown), Erika Vacchelli(United States Golf Association), Dmitry I. Gabrilovich(AstraZeneca (Netherlands)), Jean‐Yves Blay(Université Claude Bernard Lyon 1), François Ghiringhelli(Inserm), Anne Hosmalin(Centre National de la Recherche Scientifique), Jitka Fučíková(Charles University), Claire E. Lewis(Queen's University Belfast), Oliver Kepp(Inserm), Paweł Kaliński(Roswell Park Comprehensive Cancer Center), Abhishek D. Garg(KU Leuven), Chiara Castelli(Fondazione IRCCS Istituto Nazionale dei Tumori), Eli Gilboa(University of Miami), Jérôme Galon(Délégation Paris 5), Elisa Elena Baracco(Inserm), Philipp Beckhove(German Cancer Research Center), Laura Senovilla(Inserm), Wolf H. Fridman(Inserm), Anne Caignard(Inserm), Sacha Gnjatic(Tisch Hospital), Ron N. Apte(Ben-Gurion University of the Negev), Maha Ayyoub(Inserm), Mario P. Colombo(University of Palermo), Douglas T. Fearon(Cornell University), Axel Hoos(GlaxoSmithKline (United States)), Aled Clayton(Velindre Cancer Centre), José Manuel Bravo‐San Pedro(Biomedical Research Networking Center on Neurodegenerative Diseases), Fernando Aranda(Inserm), Madhav V. Dhodapkar(Emory University), Norma Bloy(Université Paris-Sud), Patrizia Agostinis(VIB-KU Leuven Center for Cancer Biology), Alexander Eggermont(University Medical Center Utrecht), Francesca Castoldi(Inserm), Alexander Knuth(National Center for Cancer Care and Research), Eva Klein(Karolinska Institutet), Vincenzo Cerundolo(John Radcliffe Hospital), Estaban Celis(Augusta University), Federica Cavallo(University of Turin), Aitziber Buqué(Inserm)
Cited by 469
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
|Cell Death and Differentiation|2018|6.4k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Photodynamic therapy of cancer: An update
|CA A Cancer Journal for Clinicians|2011|5.1k